Key highlights

  • (ASX: MSB) reported a massive revenue surge to US$51.3 million, largely driven by the U.S. launch of Ryoncil.
  • Ryoncil sales delivered a remarkable 93% gross margin, helping to narrow the company's net loss to US$40.2 million.
  • Management expects full-year revenue to reach between US$110 million and US$120 million.
  • (ASX: TYR)’s statutory net profit before tax surged 72.3% to $17.7 million, reflecting a lean and efficient operation.
  • EBITDA rose nearly 20%, with margins hitting 33.6% as the company optimizes its merchant acquisition costs.
  • The acquisition of Thriday and a 38% rise in transaction accounts point toward a deepening ecosystem.

While the broader market often moves in sync, Mesoblast Limited (ASX:MSB) and Tyro Payments Ltd (ASX:TYR) currently present a striking divergence. Both companies recently reported record-breaking fundamental results for H1 FY26, yet their stock charts tell a story of aggressive selling and bearish signals.

(ASX:MSB): Resilient Revenue Growth Amid Clinical Milestones

  • Mesoblast has reached a commercial inflection point, transitioning from a clinical-stage developer to a revenue-generating entity. The US$48.7 million contributed by Ryoncil in just six months underscores robust market adoption and high product economics.
  • While the company remains in a loss-making position due to heavy reinvestment in its Phase 3 pipeline for chronic low back pain and heart failure, its net operating cash expenditure is projected to decline throughout the second half of the year.

(ASX:TYR): Efficiency-Driven Recovery Under New Leadership

  • Tyro has entered 2026 with a clear focus on "supercharging" its growth engine under new CEO Nigel Lee. The company's 64% operating efficiency ratio, a massive improvement from 78% in FY22, demonstrates that its cost-discipline strategy is effectively translating revenue into cash flow.
  • While the core payments business remains the primary driver, the diversification into integrated banking is deepening merchant relationships and providing a higher-margin revenue stream that differentiates Tyro from generic merchant acquirers.

Associated Risks

  • Despite the fundamental pivot, Mesoblast (ASX:MSB) remains a high-risk "speculative" play. The market's recent negative reaction to the guidance highlights the tension between optimistic long-term narratives and the immediate reality of ongoing losses.
  • Key risks include the potential for regulatory delays in its upcoming BLA submissions for Revascor and the inherent uncertainty of clinical trial outcomes, which could necessitate further capital raises if revenue growth fails to reach breakeven targets fast enough.
  • Notwithstanding the stellar half-year results, Tyro (ASX:TYR) faces several headwinds in the second half of the year. Management anticipates a "step up" in operating expenses of approximately $10 million in H2 FY26, driven by salary increases, marketing investments, and higher AML compliance costs.
  • Additionally, the Bendigo Alliance volumes saw a 10% decline this half, highlighting competitive pressures in the non-core partner segment. Macroeconomic uncertainties, such as changes to government Bulk Billing rates impacting the health vertical, also remain key factors to monitor.

Technical Outlook

While the fundamentals show improvement, the technical price action is currently exhibiting a sharp bearish shift.

Mesoblast (ASX:MSB)

MSB’s Daily Price Chart (at the closing price of 27th February 2026). Powered by: tradingview.com

  • On the daily chart, MSB has formed a Bearish Engulfing followed by a Three Outside Down candlestick pattern, signaling aggressive selling pressure.
  • Additonally, a significant breakaway gap to the downside has occurred, often a precursor to a continued downward move or a retest of lower support zones.
  • Strong trading volume on the decline suggests the stock may be heading toward the $1.92 support level, with a secondary historical floor at $1.515 if the bearish momentum persists.

Tyro (ASX:TYR)

TYR’s Daily Price Chart (at the closing price of 27th February 2026). Powered by: tradingview.com

  • On the daily chart, TYR’s stock price completed a large Head and Shoulders pattern extending from July 2025 to January 2026, which suggests a short-term trend reversal from upward to downward.
  • Following the initial breakdown below the neckline, the stock exhibited a "Dead cat bounce", a brief recovery that failed to reclaim the neckline before resuming its downward trajectory.
  • On 02 March 2026, the stock price broke below its previous trough on strong trading volume, indicating sustained bearish momentum. If this momentum continues, the pattern’s projected target of $0.69, or the critical support zones between $0.645 and $0.625, may serve as areas for potential accumulation.

Bottom Line

  • While both companies have reached major fundamental milestones, MSB with its high-margin revenue surge to US$51.3 million and TYR with a 72.3% leap in statutory profit, their technical charts are dominated by bearish structures. The emergence of high-volume breakaway gaps and Head and Shoulders patterns suggests that the market is currently prioritizing execution risks, such as Tyro's anticipated $10 million expense increase and Mesoblast's ongoing losses, over their record-breaking results.
  • Until these stocks find a firm technical floor at the identified support zones ($1.92 for MSB and $0.69 for TYR), the strong fundamental turnaround remains overshadowed by aggressive short-term selling pressure.